Breakthrough Discovery for Leukaemia Therapy
Scientists at the Department of Cancer Research (DoCR) at the Luxembourg Institute of Health (LIH) have revealed the ground-breaking therapeutic potential of the compound FL3 in inhibiting oncogene translation and rewiring cancer cell metabolism, offering new hope for patients with chronic lymphocytic leukaemia (CLL), a prevalent form of cancer characterised by the overproduction and accumulation of dysfunctional B lymphocytes in various parts of the body. Click to read more...
Etienne Moussay Anne Largeot Luxembourg National Research Fund Luxembourg Institute Of Health Swedish Children Cancer Foundation Swedish Cancer Society
Source: labmate-online.com